2.2.0.25falsefalse0201 - Disclosure - The Companytruefalsefalse1falsefalseUSDfalsefalse4/1/2010 - 3/31/2011
USD ($)
USD ($) / shares
$Apr-01-2010_Mar-31-2011http://www.sec.gov/CIK0000874663duration2010-04-01T00:00:002011-03-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0alks_NatureOfOperationAbstractalksfalsenadurationNature of operationfalsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNature of operationfalsefalse3false0us-gaap_NatureOfOperationsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations-->
<div align="left" style="margin-left: 0%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">
</font></b>
</div>
<div align="left" style="margin-top: 0pt; font-size: 1pt"></div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">
<!-- XBRL,ns -->
<!-- xbrl,nx -->
</font></b>
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent; text-align: left">
<tr>
<td width="3%"></td>
<td width="97%"></td>
</tr>
<tr valign="top">
<td>
<b><font style="font-family: 'Times New Roman', Times">1.  </font></b>
</td>
<td>
<b><font style="font-family: 'Times New Roman', Times">THE
COMPANY</font></b>
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
Alkermes, Inc. (as used in this section, together with our
subsidiaries, “Alkermes” or the “Company”)
is a fully integrated biotechnology company committed to
developing innovative medicines to improve patients’ lives.
The Company is headquartered in Waltham, Massachusetts and has a
research facility in Massachusetts and a commercial
manufacturing facility in Ohio. The Company developed,
manufactures and commercializes
VIVITROL<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(naltrexone for extended-release injectable suspension) for
alcohol dependence and for the prevention of relapse to opioid
dependence, following opioid detoxification. The Company also
manufactures
RISPERDAL<sup style="font-size: 85%; vertical-align: text-top">®</sup>
CONSTA<sup style="font-size: 85%; vertical-align: text-top">®</sup>
[(risperidone) long-acting injection] for schizophrenia and
bipolar I disorder. The Company’s pipeline includes
extended-release injectable and oral products for the treatment
of prevalent, chronic diseases, such as central nervous system
(“CNS”) disorders, reward disorders, addiction,
diabetes and autoimmune disorders.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
falsefalse12The CompanyUnKnownUnKnownUnKnownUnKnownfalsetrue